New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 9, 2014
07:15 EDTMYL, TEVATeva, others fined $583.4M by EU regulators, Reuters says
Teva (TEVA), Servier and four other drug companies were fined a total of $583.4M by EU antitrust regulators for blocking less-expensive generic medicine, according to Reuters, citing a statement from European Competition Commissioner Joaquin Almunia. The other penalized companies were Unichem and its subsidiary Niche, as well as Matrix, which is now known as Mylan (MYL) Laboratories, and Slovenian peer Krka and Lupin. Reference Link
News For TEVA;MYL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 5, 2015
08:31 EDTTEVAANI Pharmaceuticals acquires generic drug product from Teva
ANI Pharmaceuticals (ANIP) announced that it has acquired the approved abbreviated new drug application for Flecainide Acetate tablets USP 50mg, 100mg and 150mg, previously marketed by Teva Pharmaceuticals (TEVA). According to IMS Health, the overall market for this product was approximately $39M in 2014. ANI has forty-seven generic drug products under development addressing a total annual market size of approximately $3B, based on data from IMS Health.
07:57 EDTMYLMylan coverage resumed with an Overweight at Morgan Stanley
Subscribe for More Information
March 2, 2015
18:52 EDTMYLOn The Fly: After Hours Movers
Subscribe for More Information
16:17 EDTMYLMylan sees FY15 adjusted gross margin 53%-55%
Subscribe for More Information
16:16 EDTMYLMylan sees FY15 operating cash flow $1.6B-$1.8B; FY15 CapEx $400M-$500M
16:14 EDTMYLMylan says 'off to great start in 2015'
The company said, "We are off to a great start in 2015 with the recent completion of our acquisition of Abbott's non-U.S. developed markets specialty and branded generics business and the announcement of our proposed acquisition of Famy Care's women's health care businesses, and we expect that Mylan will deliver 33% revenue growth and 21% adjusted diluted EPS growth on a constant currency basis in 2015. In addition to these exciting activities, and as we have previously stated, you can continue to expect us to aggressively pursue additional acquisition opportunities that make financial and strategic sense for our company."
16:13 EDTMYLMylan sees FY15 adjusted EPS $4.00-$4.30, consensus $4.16
Subscribe for More Information
16:12 EDTMYLMylan reports Q4 adjusted EPS $1.05, consensus $1.05
Reports Q4 revenue $2.08B, consensus $2.07B.
15:23 EDTMYLNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Mylan (MYL), consensus $1.05... Nabors Industries (NBR), consensus 39c... PRA Group (PRAA), consensus $1.11... Caesars Entertainment (CZR), consensus ($1.65)... Cumulus Media (CMLS), consensus 9c... Arena Pharmaceuticals (ARNA), consensus (12c)... Palo Alto Networks (PANW), consensus 17c... Guidewire Software (GWRE), consensus 11c... McDermott International (MDR), consensus (6c)... Salix Pharmaceuticals (SLXP), consensus (25c)... Matador Resources (MTDR), consensus 19c... Sanchez Energy (SN), consensus (11c).
08:47 EDTMYLMylan volatility elevated into Q4 and outlook
Subscribe for More Information
08:24 EDTTEVATeva announces sale of Sellersville, PA facility to G&W Laboratories
Subscribe for More Information
07:20 EDTTEVACowen to hold a conference
Subscribe for More Information
February 27, 2015
15:09 EDTMYLMylan files to sell 110M ordinary shares for selling shareholders
12:35 EDTMYLMylan completes acquisition of assets from Abbott
Mylan N.V. and Mylan (MYL) announced the successful completion of the acquisition of Abbott Laboratories' (ABT) non-U.S. developed markets specialty and branded generics business. Under the previously announced terms of the transaction agreement, Abbott received 110M shares of Mylan N.V., resulting in former Mylan shareholders now owning approximately 78% of Mylan N.V. and Abbott now owning approximately 22% of Mylan N.V. Mylan Inc. and Abbott's non-U.S. developed markets specialty and branded generics business have been reorganized under Mylan N.V., a new public company organized in the Netherlands. Mylan N.V. will be led by the former Mylan Inc. executive team. The company will trade on Nasdaq under the ticker symbol MYL.
February 25, 2015
08:05 EDTTEVATeva says FDA accepts CEP-33237 NDA for review
Subscribe for More Information
February 24, 2015
09:02 EDTTEVATeva announces phase 2b study of TEV-48125 achieved endpoints
Subscribe for More Information
February 23, 2015
15:04 EDTTEVATeva announces publication of data on Phase III trials of reslizumab
Subscribe for More Information
07:16 EDTMYLMylan signs exclusive agreement with Gilead to distribute Solvaldi, Harvoni
Subscribe for More Information
February 20, 2015
08:04 EDTTEVATeva to present new respiratory data at AAAAI
Teva Pharmaceutical Industries announced that four company-sponsored abstracts will be presented at the 2015 Annual Meeting of the American Academy of Allergy, Asthma and Immunology, or AAAAI, in Houston, Texas. Data to be presented include two replicate 52-week Phase III global studies of the company’s anti-IL5 monoclonal antibody, reslizumab, in patients with asthma and elevated blood eosinophils who were inadequately controlled on medium-to-high doses of inhaled corticosteroids with or without an additional controller. The data are scheduled for presentation on Monday, February 23 during an oral session titled “Asthma Therapy and Mechanisms.” Also to be presented are two Phase III studies of beclomethasone dipropionate 40mcg, which gained FDA approval in December 2014, and is now available for the treatment of nasal symptoms associated with allergic rhinitis in children 4-11 years of age. In addition, a dose-response study evaluating the safety and efficacy of fluticasone/salmeterol multidose dry-powder inhaler in patients 12 years of age and older with persistent asthma will be presented.
07:08 EDTTEVA, MYLAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use